| Literature DB >> 31330023 |
Elin Børøsund1, Cecilie Varsi1, Matthew M Clark2, Shawna L Ehlers2, Michael A Andrykowski3, Hilde Renate Sætre Sleveland1, Anne Bergland1, Lise Solberg Nes1,2,4.
Abstract
Psychosocial eHealth intervention programs for cancer survivors are still in their infancy, with inconsistent findings so far in the scientific literature. The aim of this study was to explore system use, usefulness, ease of use, and preliminary effects of Stress Proffen, an app-based cognitive-behavioral stress management intervention for patients with cancer. A feasibility pilot project tested the intervention with cancer survivors (N = 25). The intervention contained (a) one face-to-face introduction session, (b) 10 app-based modules with stress management educational material and exercises, and (c) one follow-up phone call. Post-intervention interviews were conducted and user log-data were extracted. Outcome measures-Perceived Stress Scale (PSS), Anxiety and Depression (Hospital Anxiety and Depression Scale [HADS]), Health-Related Quality of Life (HRQoL; SF-36), and Self-Regulatory Fatigue (SRF-18)-were completed at baseline and post-intervention. Participants were primarily women (84%), age 34-71 (mean 48) and represented a variety of cancer diagnoses (majority breast cancer: 40%). Twenty-two participants completed all (pre-post) questionnaires. Sixteen participants (67%) completed at least 7 of 10 modules within the 8-week study period. Post-intervention interviews described StressProffen as providing a new, appreciated, and easily accessible stress management tool for the cancer survivors. Dependent/paired t-tests showed significant pre-post intervention effects with significant decrease in stress (p = .008), anxiety (p = .019), and self-regulatory fatigue (p = .025), and improved HRQoL (Role Physical, General Health, Vitality, and Role Emotional, all p's <.01). App-based stress management interventions such as StressProffen can provide appreciated support for cancer survivors, should be easy to use, can provide significant stress reduction, and improve emotional well-being. Further testing in a randomized controlled trial is warranted and is in progress. Clinicaltrials.gov: NCT0293961.Entities:
Keywords: Cancer; Psycho-oncology; Stress management; User-centered design; eHealth; mHealth
Mesh:
Year: 2020 PMID: 31330023 PMCID: PMC7413188 DOI: 10.1093/tbm/ibz062
Source DB: PubMed Journal: Transl Behav Med ISSN: 1613-9860 Impact factor: 3.046
Fig. 1StressProffen screenshots.
Baseline demographic and clinical characteristics of cancer survivors included in the app-based stress management intervention (N = 25)
| Characteristics | Cancer survivors ( | |||
|---|---|---|---|---|
| Median | Range |
| % | |
| Age (years) | 46 | 34–71 | ||
| Months since diagnosis | 18 | 0.5–78 | ||
| Gender | ||||
| Female | 21 | 84 | ||
| Male | 4 | 16 | ||
| Marital status | ||||
| Married/cohabitating | 18 | 84 | ||
| Single/divorced | 7 | 16 | ||
| Education | ||||
| Elementary/high school | 5 | 20 | ||
| University/college ≤4 years | 8 | 32 | ||
| University/college >4 years | 12 | 48 | ||
| Employment status | ||||
| Full-time/part-time work | 8 | 32 | ||
| Sick leave/disability benefits | 14 | 56 | ||
| Retired/other | 3 | 12 | ||
| Diagnosis | ||||
| Breast cancer | 10 | 40 | ||
| Othera (see below) | 15 | 60 | ||
| Metastatic disease | ||||
| Yes | 8 | 32 | ||
| No | 17 | 68 | ||
| Treatment | ||||
| Operation | 18 | 72 | ||
| Chemotherapy | 16 | 64 | ||
| Hormone therapy | 10 | 40 | ||
| Radiation | 9 | 36 | ||
| Immune therapy | 1 | 4 |
aOther includes: cancer of bladder, cervix, ovary, fallopian tube, colon, pancreas, peritoneal, lung, prostate, endometriosis sarcoma, melanoma, chronic myelogenous leukemia, leukemia, and brain tumor.
Pre–post intervention changes in perceived stress, anxiety, depression, HRQoL, and self-regulation (n = 22)
| Baseline ( | Post-intervention ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Psychosocial outcomes | Mean | SD | Mean | SD | Mean diff. | 95% CI of diff. | SD diff. |
|
|
| Perceived stress (PSS-14) | 25.7 | 7.7 | 21.8 | 7.1 | 4.0 | 1.1–6.8 | 6.4 | 0.62 | .008 |
| Anxiety (HADS-A) | 8.1 | 4.2 | 6.4 | 3.5 | 1.7 | 0.3–3.1 | 3.2 | 0.54 | 019 |
| Depression (HADS-D) | 6.1 | 3.9 | 5.3 | 3.6 | 0.7 | −0.3 to 1.7 | 2.3 | 0.32 | .148 |
| Anxiety and depression | 14.2 | 7.4 | 11.7 | 6.9 | 2.5 | 0.4–4.6 | 4.7 | 0.52 | .024 |
| HRQoL (SF-36)a | |||||||||
| Physical Functioning | 73.9 | 21.6 | 42.0 | 31.2 | 31.8 | 15.7–48.0 | 36.4 | 0.87 | .001 |
| Role Physical | 29.5 | 39.1 | 80.2 | 22.8 | −50.7 | −69.3 to −32.1 | 42.0 | 1.21 | <.001 |
| Bodily Pain | 59.7 | 25.1 | 39.8 | 39.8 | 19.9 | 2.0–37.8 | 40.4 | 0.49 | .031 |
| General Health | 46.8 | 22.7 | 66.5 | 22.7 | −19.7 | −32.8 to −6.5 | 29.6 | 0.67 | .005 |
| Vitality | 39.3 | 19.5 | 53.9 | 21.8 | −14.5 | −24.0 to −5.1 | 21.3 | 0.68 | .004 |
| Social Functioning | 50.6 | 27.7 | 44.5 | 17.6 | 6.0 | −5.0 to 17.1 | 24.9 | 0.24 | .270 |
| Role Emotional | 34.8 | 37.8 | 65.9 | 25.9 | −31.1 | −50.4 to −11.7 | 43.7 | 0.71 | .003 |
| Mental Health | 64.4 | 17.1 | 75.8 | 37.3 | −11.4 | −25.2 to 2.4 | 31.1 | 0.37 | .101 |
| SRF-18 | 51.6 | 11.2 | 48.1 | 10.4 | 3.6 | 0.5–6.7 | 7.0 | 0.52 | .025 |
CI confidence interval; d, Cohen’s d; HADS Hospital Anxiety and Depression Scale; HRQoL Health-Related Quality of Life; PSS Perceived Stress Scale; SF-36 Short-Form Health Survey; SRF-18 18-item Self-Regulatory Fatigue.
aHigher scores indicate better function.
Correlations of intervention completer status, selected background variables, and baseline psychosocial measures (N = 25)
| Completer status | Age | Gender | Education | Metastasis | Months since diagnosis | PSS | HADS – Anxiety | HADS – Depression | HRQoL – Physical Functioning | HRQoL – Role Physical | HRQoL – Bodily Pain | HRQoL – General Health | HRQoL – Vitality | HRQoL – Social Functioning | HRQoL – Role Emotional | HRQoL – Mental Health | SRF | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention completer status | 1 | |||||||||||||||||
| Age | .27 | 1 | ||||||||||||||||
| Gender | −.13 | .12 | 1 | |||||||||||||||
| Education | .16 | .11 | .12 | 1 | ||||||||||||||
| Metastasis | −.16 | .00 | −.17 | −.08 | 1 | |||||||||||||
| Months since diagnosis | −.00 | −.29 | −.27 | −.21 | −.16 | 1 | ||||||||||||
| Perceived stress (PSS) | −.40* | −.21 | −.08 | −.47* | .07 | .10 | 1 | |||||||||||
| HADS – Anxiety | −.15 | −.10 | .00 | −.44* | .02 | .16 | .76** | 1 | ||||||||||
| HADS – Depression | −.12 | .01 | .05 | −.39 | −.17 | .10 | .54** | .62** | 1 | |||||||||
| HRQoL – Physical Functioning | .02 | −.47* | .23 | .06 | −.02 | −.21 | .10 | .06 | −.09 | 1 | ||||||||
| HRQoL – Role Physical | .05 | −.24 | .02 | .16 | .16 | −.12 | −.23 | −.18 | −.31 | .30 | 1 | |||||||
| HRQoL – Bodily Pain | −.09 | −.08 | .11 | .02 | .24 | −.26 | −.29 | −.39 | −.26 | .14 | .56** | 1 | ||||||
| HRQoL – General Health | .48* | .40* | .09 | .26 | .13 | −.26 | −.43* | −.35 | −.48* | −.01 | .28 | .11 | 1 | |||||
| HRQoL – Vitality | .27 | .14 | .25 | .46* | −.20 | −.22 | −.68** | −.66** | −.57** | .26 | .24 | .20 | .61** | 1 | ||||
| HRQoL – Social Functioning | −.07 | −.24 | .25 | .36 | .05 | −.13 | −.27 | −.49* | −.47* | .56** | .58** | .44* | .38 | .49* | 1 | |||
| HRQoL – Role Emotional | .10 | .21 | −.02 | .35 | .02 | .17 | −.59** | −.65** | −.33 | −.14 | .14 | .20 | .39 | .65** | .,41* | 1 | ||
| HRQoL – Mental Health | .02 | −.04 | .05 | .46* | .02 | −.06 | −.59** | −.74** | −.64** | −.03 | .22 | .31 | .43* | .53** | .64** | .57** | 1 | |
| SRF | −.29 | −.31 | −.14 | −.40* | .22 | .29 | .75** | .65** | .50* | .23 | −.16 | −.19 | −.32 | −.69** | −.09 | −.58** | −.40* | 1 |
HADS Hospital Anxiety and Depression Scale; HRQoL Health-Related Quality of Life; PSS Perceived Stress Scale; SRF Self-Regulatory Fatigue.
*p <.05, **p <.01.